Literature DB >> 7890063

Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo.

K J Chang1, T T Lee, G Linares-Cruz, S Fournier, B de Ligniéres.   

Abstract

OBJECTIVE: To study the effect of E2 and P on the epithelial cell cycle of normal human breast in vivo.
DESIGN: Double-blind, randomized study. Topical application to the breast of a gel containing either a placebo, E2, P, or a combination of E2 and P, daily, during the 10 to 13 days preceding breast surgery. PATIENTS: Forty premenopausal women undergoing breast surgery for the removal of a lump. MAIN OUTCOME MEASURES. Plasma and breast tissue concentrations of E2 and P. Epithelial cell cycle evaluated in normal breast tissue areas by counting mitoses and proliferating cell nuclear antigen immunostaining quantitative analyses.
RESULTS: Increased E2 concentration increases the number of cycling epithelial cells. Increased P concentration significantly decreases the number of cycling epithelial cells.
CONCLUSION: Exposure to P for 10 to 13 days reduces E2-induced proliferation of normal breast epithelial cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890063

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis.

Authors:  B Formby; T S Wiley
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

Review 2.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

Review 3.  Progesterone and Breast Cancer.

Authors:  Britton Trabert; Mark E Sherman; Nagarajan Kannan; Frank Z Stanczyk
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

4.  Enhanced oromucosal delivery of progesterone via hexosomes.

Authors:  Nitin K Swarnakar; Vikas Jain; Vaibhav Dubey; Dinesh Mishra; N K Jain
Journal:  Pharm Res       Date:  2007-09-08       Impact factor: 4.200

5.  Exercise and breast cancer prevention.

Authors:  Leslie Bernstein
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

6.  Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Authors:  Agnès Fournier; Alban Fabre; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Franco Berrino; Françoise Clavel-Chapelon
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

7.  Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.

Authors:  Andres D Ruiz; Kelly R Daniels; Jamie C Barner; John J Carson; Christopher R Frei
Journal:  BMC Womens Health       Date:  2011-06-08       Impact factor: 2.809

8.  Oral progestagens before menopause and breast cancer risk.

Authors:  A Fabre; A Fournier; S Mesrine; J Desreux; A Gompel; M-C Boutron-Ruault; F Clavel-Chapelon
Journal:  Br J Cancer       Date:  2007-02-13       Impact factor: 7.640

9.  Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause.

Authors:  J C Prior
Journal:  Facts Views Vis Obgyn       Date:  2011

10.  Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.

Authors:  D F Hargreaves; F Knox; R Swindell; C S Potten; N J Bundred
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.